What amount sold does Georgiamune, Inc. report in Form D filings?

The latest linked filings report $92.7M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Georgiamune, Inc.'s most recent SEC filing?

Georgiamune, Inc.'s most recent Form D filing was on 2026-08-17.

How many investors does Georgiamune, Inc. have?

The most recent Form D filing lists 26 investor(s).

What type of securities does Georgiamune, Inc. offer?

Georgiamune, Inc.'s SEC Form D filings indicate equity offerings.

Georgiamune, Inc.

CIK: 0002148230·Biotechnology·Gaithersburg, MD·Corporation

Reported Sold

$92,692,709

Total Filings

Identified Offerings

Last Filed

Aug 17, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Aug 17, 2026Form D — New notice

Reported sold: $92,692,709 · Target: $131,852,011

Rule 506(b)·26 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$92,692,709

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Filing History

Date	Type	Offering target	Reported sold	Investors
Aug 17, 2026	New	$131,852,011	$92,692,709	26

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Kaigene, Inc.

Biotechnology

Offering target: $73,350,000

Filed Oct 14, 2026